Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21)

The summary for the Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21): The purpose of this funding opportunity announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection.

Federal Grant Title:	Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-17-282
Type of Funding:	Grant
CFDA Numbers:	93.855, 93.856
CFDA Descriptions:	Information not provided
Current Application Deadline:	September 7th, 2020
Original Application Deadline:	September 7th, 2020
Posted Date:	May 12th, 2017
Creation Date:	May 12th, 2017
Archive Date:	October 13th, 2020
Total Program Funding:
Maximum Federal Grant Award:	$200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	May 12th, 2017

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PA-17-282.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Immunobiology of Xenotransplantation (U19 Clinical Trial Not Allowed); • Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Anti...; • Immunobiology of Xenotransplantation (U01 Clinical Trial Not Allowed); • Limited Interaction Targeted Epidemiology: Epidemiology of Transmission and Treatment of H...; • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...